PolyPid Presents today at The Raymond James Human Health Innovation Conference
PolyPid (Nasdaq: PYPD) announced a presentation by CFO Dikla Czaczkes Akselbrad at The Raymond James Human Health Innovation Conference on June 23, 2021, at 9:20 am EDT. The conference aims to highlight innovations in healthcare, with PolyPid focusing on improving surgical outcomes through its proprietary PLEX technology, which enhances drug delivery. The lead candidate, D-PLEX100, is undergoing Phase 3 trials for preventing surgical site infections. The presentation will be available on the company’s Investor Relations site for 90 days following.
- PolyPid's lead product D-PLEX100 is in Phase 3 clinical trials, which may boost investor confidence.
- The presentation at a notable conference could increase visibility and interest in PolyPid's therapeutic innovations.
- None.
Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT
PETAH TIKVA, Israel, June 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vice President and Chief Financial Officer will present today at The Raymond James Human Health Innovation Conference at 9:20 am EDT.
The presentation will be webcast live and archived 90 days on PolyPid's Investor Relations website, which can be found at: https://investors.polypid.com/events-and-presentations/events.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ongoing clinical trials, plans to use the guidance provided by the FDA to progress with its SHIELD I program, the timing of top-line results of the SHIELD I trial, and the size and design of the SHIELD I trial. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 5, 2021. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Corporate Contact
PolyPid, Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700
Investor Contact
Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com
Media Contact
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com
FAQ
What is the significance of PolyPid's presentation at The Raymond James Human Health Innovation Conference?
What is PYPD's lead product candidate and its current trial phase?
When is PolyPid's presentation scheduled?
